PROCR and cutaneous mastocytosis: The development of therapies and vaccines to create a narrowly reactive antibody-response prevention and ideal reversal of IE adherences to ICAM1 and EPCR, which are reported as main receivers in CM pathogenesis will be an obvious aim alongside the existing initiative to improve VAR2CSA-based vaccines.